T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
Frequency and Abundance of T790M Mutation on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment Failure: a Perspective Observational Study
Sponsor: First People's Hospital of Hangzhou
This observational or N/A phase trial investigates Non-Small-Cell Lung Cancer Metastatic and Non-small Cell Lung Cancer Stage III and is currently completed. First People's Hospital of Hangzhou leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Jan 2021 — Dec 2022 [monthly]
Completed
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First People's Hospital of Hangzhou
For direct contact, visit the study record on ClinicalTrials.gov .